CD33 and acute myeloid leukemia: Numerous CAR-T cell clinical trials are enrolling patients with AML, most of which involve targeting of CLL-1 (also known as CLEC12A), CD33, or CD123; however, the clinical efficacy of these therapies remains uncertain28.